FDA Determines Regulatory Review Period for DERAMAXX Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for DERAMAXX, a patent extension application submitted to the Department of Commerce, and is publishing this notice as required by law.